Combination therapy for fatty liver, obesity, and type 2 diabetes
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests whether adding a new medicine, CS0159, to a standard diabetes drug (semaglutide) can improve liver health and blood sugar in people with fatty liver disease, obesity, and type 2 diabetes. It may help reduce liver fat and support weight loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have type 2 diabetes and are obese (BMI between 30 and 45).
- Your liver has at least 10% fat, measured by a special MRI scan within the last 3 months.
- You manage your diabetes with diet and exercise only (no diabetes pills or insulin) for at least 3 months.
- You are willing to keep the same diet and exercise habits for the whole study and follow the study checks and medication schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how semaglutide (a diabetes medication also used for weight) affects fatty liver and the liver’s response to sugar. It may help people with non-alcoholic fatty liver disease understand whether the drug improves liver fat and related changes.
This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.
This study tests whether semaglutide, a medicine that helps control blood sugar and reduce weight, can benefit adults with type 1 diabetes who are overweight. If you qualify, you may receive the drug or a placebo, and the study team will monitor your health closely.
This study tests a new medicine, NNC0662-0419, in people with type 2 diabetes. You must be willing to lose a lot of weight (more than a quarter of your current weight) as part of the study to see if the medicine helps lower blood sugar.
This trial tests whether mazdutide, a new medicine, can improve blood sugar and reduce liver fat in people with type 2 diabetes and moderate-to-severe fatty liver who are already taking semaglutide (a weekly injection). It aims to find a more effective treatment for these combined conditions.
This study tests whether an oral medication called semaglutide can help people with type 2 diabetes, fatty liver, and kidney problems. It aims to see if it can improve kidney function and liver health.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.